ALEVIAN DUO


Cápsulas.


 
ALEVIAN DUO - BIBLIOGRAFIA
1  Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108. 2  Drossman DA, Corazziari E, Talley NJ, Grant Thompson W, Whitehead WE. Rome II, The Functional Gastrointestinal Disorders, 2nd ed McLean, Degnon Associates, 2000: 299-350; 351-432 3  Camilleri M, Spiller R. Irritable Bowel Syndrome, W.B. Saunders, 2002: 173-178. 4.  Eglen RM, Hedge SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996,48: 531-65. 5.  McFadzean I, Gibson A The developing relationship between receptor-operated and store­operated calcium channeis in smooth muscle. Br J Pharmacol, 2002; 135: 1-13 6.  Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Current Pharmaceutical Design, 2004;10: 3561-68. 7.  Wittmann T, Rosztozcy A, Feher A Surface electromyography in irritable bowei syndrome (IBS). A new approach to colonic motility. Neurogastroenterology & Motility, 1998: 10(5): 477. 8.  Yun Dai, Jian-Xiang Liu, Jun-Xia Li, Yun-Feng Xu. Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. Worl J Gastroenterol, 2003; 9(3): 557-561 9.   Jailwala J, Imperiale TF, Kroenke K. Pharmacological treatment of irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Int Med, 2000; 133: 136-47. 10. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61 11 Poynard T, Regimbeau C, Benhamou Y. Review: Smooth muscle relaxants improve symptoms and reduce pain in irritable bowel syndrome. Am Coll Physic Journal, 2001; 135: 53-5. 12 Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowei syndrome. Am J. Gastroenterol, 2001; 96: 3341-7. 13 Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med, 1975; 293: 524-6. 14. Serra J, Azpiroz F, Malagelada JR. Perception and reflex responses to intestinal distention in humans are modified by simultaneous or previous stimulation. Gastroenterology, 1995; 109: 1742-­9. 15. Serra J, Azpiroz F, Malagelada JR. Modulation of gut perception in humans by spatial summation phenomena. J Physiol, 1998; 506: 579-87. 16. Serra J, Azpiroz F, Malagelada J-R. Intestinal gas dynamics and tolerance in humans. Gastroenterology, 1998; 115: 542-50. 17. Serra J, Azpiroz F, Malagelada J-R. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol, 2001, 281: 138-­143 18. Serra J, Azpiroz F, Malagelada J-R. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut, 2001; 48: 14-19. 19. Serra J, Salvioli B, Azpiroz F, Malagelada J-R. Lipid-induced gas retention in irritable bowel syndrome. Gastroenterology, 2002; 123: 700-706. 20. Salvioli B, Serra J, Azpiroz F, Lorenzo C, Aguade S, Castell J, Malagelada JR. Origin of gas retention and symptoms in patients with bloating. Gastroenterology, 2005; 128(3): 574-9. 21 Holtmann G, Gschossmann J, Karaus M, Fischer T, Becker B, Mayr P, Gerken G. Randomized double-blind comparison of simethicone and cisapride in functional dyspepsia. Aliment Pharmacol Ther, 1999; 13: 1459-64. 22 Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology, 1995; 109: 671-80. 23 Ansorg R, Von Recklinghausen G, Heintschel VH. Susceptibility of Helicobacter pylori to simethicone and other nonantibiotic drugs. J Antimicrob Chemother, 1996; 37: 45-52 24. Kaplan MA, Prior MJ, Ash RR, McKonly Kl, Helzner EC, Nelson EB. Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort. A randomized controlled trial. Arch Fam Med, 1999; 8(3): 243-8. 25. Ching-Liang Lu, Chih-Yen Chen, Full-Young Chang, Shen-Shong Chang, Lih-Jiun Kang, Rei-Hwa Lu, Shou-Dong Lee. Irritable Bowel Syndrome, Colitis and Colorectal Cancer. Journal of Gastroenterology and Hepatology, 2000 15, 925-930. 26. Susan K. Hadley, M.D, Stephen M. Gaarder, Ph. D. Treatment of Irritable Bowel Syndrome. American Family Physician, 2005; 72: 12; 2501-06. 27. The United States Pharmacopoeia USP 28/NF 23 The Official Compendia of Standards, The United States Pharmacopeial Convention, Inc. 2005, 1768, 1769. 28. Martindale, Guía Completa de Consulta Farmaco-terapéutica, Primera edición española de la trigésimo-tercera edición inglesa, Barcelona, España. 2003, 1379, 1380, 1603, 1604. 29. The Merck Index. An Enciclopedia of Chemicals, Drugs and Biologicals, Merck & Co, Inc, 13a. edición, Whitehouse Station, NJ. 2001, p 566, 1333 30. Goodman & Gilman, Las Bases Farmacológicas de la Terapéutica, Vol. 1, Mc Graw-Hill Interamericana, 9a. Edición. 1996, p 975. Hecho en México por: Gelcaps Exportadora de México, S. A de C. V. Acondicionado y distribuido por: NYCOMED, S. A de C. V. Reg. Núm. 159M2006, SSA IV Núm. de entrada: 07330060102166